Stem Cells in Post-Stroke Regenerative Therapy: Current Role of Wharton’s Jelly Mesenchymal Stem Cells in the Orchestrum
Open Access
- 23 July 2026
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 775
Abstract
Background/Objectives: Modern approaches for post-stroke rehabilitation cover mechanistically different ways—from physiotherapy to digital technologies. Among these approaches, stem cell-based therapy represents probably the most complex but promising strategy. Methods: We discuss the current state-of-the-art of using mesenchymal stem cells (MSCs) in post-stroke regenerative therapy. Despite relatively wide use of bone marrow and adipose tissue MSCs, these cells represent a more mature (“adult”) state, which limits their proliferative and regenerative potentials. Compared to the “adult” MSCs, less “mature” MSCs obtained from umbilical cord, specifically Wharton’s jelly MSCs (WJ-MSCs), demonstrate unique functional capabilities and are free from certain technical and ethical issues. Results: The molecular and cellular mechanisms of action of WJ-MSCs are thoroughly discussed in comparison with abundantly used “adult” types of MSCs. We also comparatively evaluate their preclinical and clinical application for treating post-stroke patients. Recent findings indicate that not only MSCs but also their secretome/exosomes (cell-free product) represent a therapeutically beneficial cellular drug in post-stroke recovery. Specially designed and carefully evaluated protocols, which preserve the bioactivity of the cell-free product intact, are mentioned. Neuroprotective and neuroreparative properties of cell-free products—secretome and exosomes—derived from Wharton’s jelly MSCs are summarized. Conclusions: Cell-free products obtained from WJ-MSCs are an innovative adjunct therapy for post-stroke disorders, despite certain challenges and limitations of this type of therapy still present. By further investigation of the molecular composition and biological mechanisms of the WJ-MSC secretome and exosomes, their clinical applicability in neuroinflammatory and neurodegenerative pathologies will be promoted.Keywords
Funding Information
- Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan (BR28713159)
This publication has 286 references indexed in Scilit:
- Therapeutic Effect of Human Umbilical Cord Mesenchymal Stromal Cells Loaded With miR‐9‐5p on Hypoxic‐Ischemic Brain Damage in Neonatal RatsBrain and Behavior, 2026
- Intranasal Wharton's Jelly‐Derived Mesenchymal Stem Cell Therapy, Alone or in Conjunction With Therapeutic Hypothermia, Alleviates Neonatal Hypoxic‐Ischemic Brain Injury in MiceAnnals of Neurology, 2025
- 3D Printing for Neural Repair: Bridging the Gap in Regenerative MedicineAdvanced Materials, 2025
- Clinical Scale MSC‐Derived Extracellular Vesicles Enhance Poststroke Neuroplasticity in Rodents and Non‐Human PrimatesJournal of Extracellular Vesicles, 2025
- Allogeneic Stem Cell Therapy for Acute Ischemic StrokeJAMA Neurology, 2024
- Extracellular Matrix‐Mimetic Hydrogels for Treating Neural Tissue Injury: A Focus on Fibrin, Hyaluronic Acid, and Elastin‐Like Polypeptide HydrogelsAdvanced Healthcare Materials, 2021
- Very early versus delayed mobilisation after strokeCochrane Database of Systematic Reviews, 2018
- Comparison between the effect of human Wharton’s jelly–derived mesenchymal stem cells and levetiracetam on brain infarcts in ratsJournal of Cellular Biochemistry, 2018
- The extracellular vesicles‐derived from mesenchymal stromal cells: A new therapeutic option in regenerative medicineJournal of Cellular Biochemistry, 2018
- Freezing of Fresh Wharton's Jelly From Human Umbilical Cords Yields High Post‐Thaw Mesenchymal Stem Cell Numbers for Cell‐Based TherapiesJournal of Cellular Biochemistry, 2015